ArticleBlood research2025

Durable responses and favorable cost-effectiveness of rituximab-based chemoimmunotherapy for primary cold agglutinin disease.

Kenichi Ito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.